Articles

The histamine bucket theory

This histamine bucket is a useful visual aid in trying to understand the impact of factors contributing to histamine levels.

18.03.2022

Ask Ingrid app

A free app developed by the Food Intolerance Network, Australian Society for Public Health. It contains comprehensive information about foods containing histamine, sorbitol, gluten, lactose, fructose and FODMAPs.

18.03.2022

Baliza.de. Histamine, fructose & co food intolerance app

A smartphone app that provides practical, evidence-based information about foods containing common triggers such as histamine, tyramine, lactose, fructose, sorbitol and fructose.

18.03.2022

Monash University FODMAP app

A smartphone app developed by experts at Monash University. Contains detailed information about foods containing FODMAPs as well as a useful symptom tracker feature.

18.03.2022

Swiss Interest Group Histamine Intolerance (SIGHI)

SIGHI is an organisation that provides information about histamine-related disorders.

18.03.2022

The low histamine chef

Blogs, books and recipes written by the low histamine chef (Yasmina Ykelenstam), a health journalist who has managed her own histamine intolerance for more than 10 years.

18.03.2022

Becky's MCAS Journey

An infographic of a patient's experience with MCAS.

19.01.2022

Diagnosing MCAS Leaflet

A leaflet discussing diagnostic criteria, biomarker tests and important information for diagnosis.

19.01.2022

Mast cell activation symptoms are prevalent in Long-COVID

Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021 Nov;112:217-226. doi: 10.1016/j.ijid.2021.09.043. Epub 2021 Sep 23. PMID: 34563706; PMCID: PMC8459548.

23.12.2021

Mast Cell Action Brochure _ B&W

18.11.2021

Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome

Vadas P, Guzman J, McGillis L, Mittal N, Walsh S. Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2020;125(6):719-720. doi:10.1016/j.anai.2020.08.015

19.09.2021

The relationship between mast cell activation syndrome, postural tachycardia syndrome and Ehlers-Danlos syndrome

Wang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42(3):243-246. doi:10.2500/aap.2021.42.210022

19.09.2021

Mast cell activation syndromes and anaphylaxis: Multiple diseases part of the same spectrum

González-de-Olano D, Matito A, Alvarez-Twose I. Mast cell activation syndromes and anaphylaxis: Multiple diseases part of the same spectrum. Ann Allergy Asthma Immunol. 2020;124(2):143-145.e1. doi:10.1016/j.anai.2019.11.023

19.09.2021

Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience

Kim JH, Xi S, Ference EH, Ge M, Liu MM, Wrobel BB. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. Int Forum Allergy Rhinol. 2020;10(8):996-1000. doi:10.1002/alr.22558

19.09.2021

Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management

Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7(4):1097-1106. doi:10.1016/j.jaip.2019.02.002

19.09.2021

Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014;113(1):115-116. doi:10.1016/j.anai.2014.05.001

19.09.2021

Timing of response and long term efficacy of Omalizumab in non-clonal mast cell activation syndrome: A case series.

Caminati M, Olivieri E, Nalin F, et al. Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series. Eur J Intern Med. 2020;71:104-106. doi:10.1016/j.ejim.2019.11.010

19.09.2021

Mast Cell Activation Disorders

Giannetti A, Filice E, Caffarelli C, Ricci G, Pession A. Mast Cell Activation Disorders. Medicina (Kaunas). 2021;57(2):124. Published 2021 Jan 30. doi:10.3390/medicina57020124

19.09.2021

Mast cell activation syndrome: Myths and realities

Zhang S, Bernstein JA. Mast cell activation syndrome: Myths and realities. Allergy Asthma Proc. 2021;42(3):198-204. doi:10.2500/aap.2021.42.210012

19.09.2021

A case of neuropathic pain in monoclonal mast cell activation syndrome

Bay JL, Sedarsky KE, Petersen MM. A case of neuropathic pain in monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2018;120(5):543-544. doi:10.1016/j.anai.2018.02.019

19.09.2021

Become a friend

Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives. Please click on Data Protection at the bottom of the page to see our Data Protection Information.

Become a friend

Donate

Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference for sufferers of MCAS.

Make a donation

Close